iPSC-Derived RPE Cells for Wet AMD Gene Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for wet age-related macular degeneration, such as intraocular injections of anti-VEGF drugs and surgical removal of choroidal neovascularization, are costly, require repeated procedures, and fail to completely halt vision loss due to damage to retinal pigment epithelium cells.
Innovation Solution
Gene therapy using iPSCs that have undergone site-directed dual-gene editing to express neurotrophic factor CNTF and anti-angiogenic miR-126, which are then differentiated into RPE cells for transplantation, aiming to repair and inhibit choroidal neovascularization.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If intraocular injection of anti-VEGF drugs is used to treat wAMD, then choroidal neovascularization can be inhibited to some extent, but the treatment requires multiple repeated injections and cannot fundamentally solve vision loss caused by RPE cell damage
Solution Approach 1:
The patent applies preliminary action by genetically modifying RPE cells ex vivo before transplantation to overexpress anti-VEGF factors. This preliminary genetic modification ensures that the transplanted cells continuously produce anti-VEGF proteins, eliminating the need for repeated post-transplantation treatments and providing long-term sustained effect.
Solution Approach 2:
The transplanted RPE cells are engineered to self-produce anti-VEGF factors through integrated genetic constructs. These modified cells autonomously secrete anti-VEGF proteins to inhibit choroidal neovascularization, making the treatment self-sustaining without requiring external repeated administrations.
2Productivity
If surgical removal of CNV is performed to directly remove neovascularization, then the procedure is more direct than drug treatment, but it removes underlying RPE cells causing retinal choroidal atrophy and prevents vision improvement
Solution Approach 1:
The patent extracts and separates the harmful function (anti-VEGF activity) from the harmful surgical intervention. Instead of surgically removing CNV and its supporting RPE cells, the invention extracts the anti-VEGF function and transfers it to lab-engineered RPE cells that are then transplanted, thereby eliminating the need for destructive surgical removal while preserving RPE cell function.
Solution Approach 2:
The patent introduces an intermediary solution by using genetically modified RPE cells as mediators. These engineered cells serve as intermediaries that perform the anti-VEGF function previously achieved only through direct surgical removal, but without the harmful side effect of removing healthy RPE cells. The intermediary cells protect vision while achieving the therapeutic goal.
3Reliability
If site-directed dual-gene editing of iPSCs is performed to express CNTF and miR-126, then neurotrophic support and anti-angiogenic activity are enhanced, but the gene editing process increases technical complexity
Solution Approach 1:
The patent merges multiple therapeutic functions into a single integrated system. The CRISPR/Cas9 gene editing process simultaneously introduces multiple genetic modifications (CNTF overexpression and miR-126 integration) into iPSCs, combining neurotrophic support and anti-angiogenic activities in one unified therapeutic approach rather than separate treatments.
Solution Approach 2:
The genetically modified RPE cells achieve multi-functionality by simultaneously performing their native RPE functions plus additional therapeutic functions: they provide neurotrophic support through CNTF overexpression, anti-angiogenic activity through miR-126, and maintain normal RPE physiology. This universal cell type performs multiple therapeutic roles that would otherwise require different treatments.
Data Source
AI summary
The present invention relates to gene therapy for wet age-related macular degeneration using iPSC-derived cells as vectors. CRISPR technology is used to perform site-directed dual gene editing of iPSCs, neurotrophic factors CNTF and miR-126 are expressed at the same time, and gene-edited IPSCs are then induced to differentiate into RPE cells. The RPE cells obtained by the induced differentiation can repair damaged RPE cells on CNV and inhibit the generation of choroidal neovascularization. In addition, the RPE cells can express the neurotrophic factors CNTF and miR-126 to fundamentally treat wet age-related macular degeneration, which has very good clinical application prospects.